"In the light of the varying rates of oseltamivir resistance among different influenza subtypes and across geographical locales, the choice of antiviral agent is often difficult. Clinical decisions should therefore be based on the perceived risk for resistance both at the individual level and global (population) level, using current local virological and epidemiological data wherever possible. A proposed model for such risk assessment is outlined in Figure 4. Ongoing incidence of oseltamivir resistance in the community in patients without evident risk factors will influence antiviral prescribing recommendations if the overall frequency of resistance rises above 10%. *****Decisions about antiviral therapy for patient management will increasingly require risk assessment and national and international antiviral policies."********
